Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $57.25

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $57.25.

Several research firms have commented on AGIO. HC Wainwright reiterated a “buy” rating and issued a $56.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, September 4th. Bank of America decreased their price target on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Weiss Ratings restated a “hold (c-)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, October 8th. Zacks Research lowered shares of Agios Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, October 6th. Finally, Scotiabank decreased their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research note on Monday, July 28th.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 3,651 shares of Agios Pharmaceuticals stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $36.77, for a total value of $134,247.27. Following the completion of the transaction, the chief financial officer directly owned 33,870 shares in the company, valued at approximately $1,245,399.90. The trade was a 9.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sarah Gheuens sold 3,302 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $43.92, for a total transaction of $145,023.84. Following the completion of the transaction, the insider owned 61,727 shares of the company’s stock, valued at $2,711,049.84. This represents a 5.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 26,984 shares of company stock valued at $1,017,811 in the last quarter. Corporate insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AGIO. NewEdge Advisors LLC purchased a new position in Agios Pharmaceuticals in the 1st quarter valued at approximately $40,000. First Horizon Corp bought a new position in Agios Pharmaceuticals in the 3rd quarter valued at $45,000. CWM LLC boosted its holdings in Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 996 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Agios Pharmaceuticals by 16.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 320 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in Agios Pharmaceuticals by 16.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 499 shares during the period.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO opened at $40.13 on Friday. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of -5.73 and a beta of 0.89. Agios Pharmaceuticals has a 52 week low of $23.42 and a 52 week high of $62.58. The firm has a 50-day moving average price of $39.62 and a two-hundred day moving average price of $35.97.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, beating the consensus estimate of ($1.93) by $0.15. The firm had revenue of $12.90 million during the quarter, compared to analyst estimates of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The company’s revenue for the quarter was up 43.3% on a year-over-year basis. During the same quarter last year, the business posted $16.22 EPS. As a group, sell-side analysts forecast that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.